Evaluation of cognitive behavioral therapy for drug use disorders in Indonesia

Evaluation of cognitive behavioral therapy for drug use disorders in Indonesia - Indo-DARPP evaluation

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000042186

Enrollment

160

Registered

2020-10-21

Start date

2021-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance use disorders

Interventions

Participants allocated to the intervention group will receive, besides treatment as usual, a group-based outpatient online Indo-DARPP session every week for 3 months (12 sessions in total), which will

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: To be eligible to participate, patients must: 1) aged between 18 and 65 years old; 2) are diagnosed as having drug or alcohol use disorder based on DSM-5; 3) have used primarily used substance for at least one day in the past one year; 4) have access to electronic devices (i.e. smartphone, mobile tablet, personal computer) with internet connection; and 5) are proficient in Indonesian.

Exclusion criteria

Exclusion criteria: 1) having comorbidity of severe psychotic or physical disorder which hinder them from providing informed consent or participating in group therapy, and 2) using residential care.

Design outcomes

Primary

Measure	Time frame
Percentage of days of being abstinent from the primarily used drug during the past 30 days assessed by weekly-basis interviews and validated by urinalysis	—

Secondary

Measure	Time frame
1. Addiction severity assessed by the Addiction Severity Index (ASI) 2. Health-related quality of life assessed by the EuroQol-5D (EQ-5D-5L) 3. Motivation to change assessed by the Action subscale of the University of Rhode Island Change Assessment (URICA) 4. Coping strategies assessed by the Brief Coping Orientations to Problems Experienced (The Brief COPE) 5. Psychiatric symptoms assessed by the Symptom Checklist 90-R (SCL-90-R) 6. Cognitive function assessed by the Rey Auditory Verbal Learning Test (RAVLT) 7. Retention in treatment defined as at least 75 percent of the planned number of therapeutic contacts during the past 3 months 8. Treatment satisfaction assessed by the Client Satisfaction Questionnaire-3 (CSQ-3) 9. Group cohesion assessed by the Group Therapy Experience Scale (GTES)	—

Measure

Time frame

1. Addiction severity assessed by the Addiction Severity Index (ASI) 2. Health-related quality of life assessed by the EuroQol-5D (EQ-5D-5L) 3. Motivation to change assessed by the Action subscale of the University of Rhode Island Change Assessment (URICA) 4. Coping strategies assessed by the Brief Coping Orientations to Problems Experienced (The Brief COPE) 5. Psychiatric symptoms assessed by the Symptom Checklist 90-R (SCL-90-R) 6. Cognitive function assessed by the Rey Auditory Verbal Learning Test (RAVLT) 7. Retention in treatment defined as at least 75 percent of the planned number of therapeutic contacts during the past 3 months 8. Treatment satisfaction assessed by the Client Satisfaction Questionnaire-3 (CSQ-3) 9. Group cohesion assessed by the Group Therapy Experience Scale (GTES)

—

Countries

Asia(except Japan)

Contacts

Public ContactChika Yamada

Kyoto University Center for Southeast Asian Studies

chika128@cseas.kyoto-u.ac.jp81-70-1780-1503

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026